Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The White House is claiming victory in a showdown with Colombia over accepting flights of deported migrants from the U.S. on Sunday, hours after President Donald Trump threatened steep tariffs on ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since December 1996 and six patient deaths.